Production and Purification of Pharmaceutically Important Fibrinolytic Enzyme from Bacillus Species

Abstract

Despite the many demonstrations of the medical and pharmacological value of thrombolytic drugs such as urokinase, t-PA,
streptokinase, staphylokinase, and others since the 1970s, these treatments may sometimes induce unwanted side effects such as bleeding
and allergic reactions. Isolation, screening, and identification of a soil bacteria for fibrinolytic enzyme synthesis are detailed in the
current results. After collecting samples from various places, the researchers utilized skimmed milk agar plates to screen for proteolytic
activity and the fibrin plate technique to assess fibrinolytic activity. The Bacillus Spp strain was shown to be capable of generating
fibrinolytic protein. Biochemical characterisation and Bergery's handbook of systemic bacteriology were used concurrently. The chosen
strain was then fermented for 5 days at 37°C and 180 rpm in basal medium. Using bovine serum albumin as a reference, the protein
content was determined using the Biuret technique. The fibrinolytic test was conducted separately. Proteins were isolated in peaks with
retention times of 2.092, 3.188, 5.178, 7.295, and 11.32 minutes throughout the three-stage purification process that began with
ammonium sulphate salting out and ended with RP-HPLC separation. A maximal activity is shown by the proportion with a retention
duration of 7.295 minutes. An ideal pH range of 7.0 to 7.5 was determined for the enzyme. At its optimal pH, enzyme activity is
maintained, but it is discovered to diminish when pH levels rise. The activity is most at 40°C, and it remains steady between 37 and 43°C
with just a little change in activity